Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2025 results exceeding the market’s revenue expectations, but sales ...

We may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...

Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 7.1% in the afternoon session after the company trimmed the upper ...

A breakthrough in our understanding of mRNA delivery systems in the body may allow for more direct treatments for ...

An mRNA cancer vaccine triggered strong immune responses and improved treatment outcomes in mice, offering a new approach to ...

The results suggest the possibility of a vaccine for HIV/AIDS, which killed more than half a million people last year.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

A nationwide Danish cohort study demonstrated no increased risk of serious adverse events following vaccination with JN.1-updated mRNA COVID-19 vaccines, reinforcing their safety profile and ...

Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.

What if mRNA vaccines could be made more powerful and less irritating? Scientists at the University of Pennsylvania have ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...